The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2023 and forecasted to 2032

The Business Research Company’s allergy immunotherapy market report forecasts the allergy immunotherapy market size to grow to $3.85 Billion by 2027, with a CAGR (compound annual growth rate) of more than 10%.

Learn More On The Allergy Immunotherapy Market Report 2023 – https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report

Allergy Immunotherapy Market Size Forecast
The global allergy immunotherapy market is expected to grow from $2.34 billion in 2022 to $2.59 billion in 2023 at a compound annual growth rate (CAGR) of 10.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The global allergy immunotherapy market size is expected to grow to $3.85 billion in 2027 at a CAGR of 10.4%.

Europe held the largest allergy immunotherapy market share, and Asia-Pacific was the fastest-growing region in 2022.

Key Allergy Immunotherapy Market Driver ­– Rise In The Prevalence Of Allergic Disorders
According to the Centres for Disease Control and Prevention (CDC), a US-based public health body, about one-third of persons aged 18 and above in the United States suffered from a seasonal allergy, skin disease, or food allergy in 2021. Seasonal allergy was the most frequent of the three allergens, affecting around one-quarter of individuals (25.7%), followed by eczema (7.3%) and food allergy (6.2%). Women were found to be more allergic to all three allergens than men. Seasonal allergy diagnoses were also common in individuals aged 18-44, 27.9% in adults aged 45-64, 26.4% in adults aged 65-74, and 21.7% in adults aged 75 and up. As a result, the growing prevalence of allergic illnesses is propelling the expansion of allergy immunotherapy market.

Request for A Sample Of The Global Allergy Immunotherapy Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9416&type=smp

Key Allergy Immunotherapy Market Trend – Product Innovations
To increase their market position, major firms in the allergy immunotherapy industry are introducing revolutionary products. For example, the European Commission, the European Union’s executive body, authorised Aimmune’s PALFORZIA as the first-ever treatment for peanut allergy in the European Union in December 2020. Aimmune Therapeutics is a biopharmaceutical business established in the United States that focuses on the development of product candidates for the treatment of peanut and other food allergies. PALFORZIA is a complex biologic medicine that is delivered using a structured dose regimen based on centuries of oral immunotherapy (OIT) research. OIT is swallowing specific allergenic proteins in small doses at first, then gradually increasing amounts, which can result in the ability to lessen allergies and the allergic response over time. This oral immunotherapy is recommended for individuals ages 4 to 17 who have a confirmed peanut allergy diagnosis.

Allergy Immunotherapy Market Segment
1) By Allergy Type: Allergic Rhinitis, Asthma, Food Allergy, Venom Allergy, Other Allergy Types
2) By Treatment: Subcutaneous Immunotherapy (SCIT), Sublingual Immunotherapy, Specific Immunotherapy (SIT)
3) By Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Allergy Immunotherapy Market Major Players and Strategies
Major players in the allergy immunotherapy market are LETI Pharma, Stallergenes Greer International AG, Allergy Therapeutics PLC., ALK-Abelló A/S, HAL Allergy B.V., DBV Technologies, Circassia Pharmaceuticals Inc., Jubilant HollisterStier LLC, Allergo Pharma, Biomay AG, Anergis SA, HollisterStier Allergy, Mylan N.V., Adamis Pharmaceuticals Corporation, Desentum Oy, and WOLW Pharma.

Nestle, a Swiss nutrition, health, and wellness firm, acquired Aimmune Therapeutics for an undisclosed sum in October 2020. Nestle will continue its relentless search of innovative, science-based nutritional solutions to help people live better lives as a result of this acquisition. Aimmune Therapeutics is a biopharmaceutical business established in the United States that is discovering and bringing novel medicines to patients with potentially fatal food allergies, as well as allergy immunotherapy.

The Allergy Immunotherapy Global Market Report 2023 covers regional data on allergy immunotherapy market size, allergy immunotherapy market trends and drivers, opportunities, strategies, and allergy immunotherapy market competitor analysis. The countries covered in the allergy immunotherapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, the UK, and the USA, and the major seven regions are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Allergy immunotherapy is a sort of treatment that is used to prevent allergic reactions to items like home dust mites, grass pollen, and bee venom. Immunotherapy entails gradually increasing the patient’s exposure to the chemical or allergen to which they are allergic.

View More Reports Related To The Allergy Immunotherapy Market –
Allergy Diagnostics Global Market Report 2023
Allergy Conjunctivitis Global Market Report 2023
Drugs For Immunotherapy Global Market Report 2023

Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]

Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on: